Please login to the form below
Oseni
This page shows the latest Oseni news and features for those working in and with pharma, biotech and healthcare.
Forest Labs agrees $1.46bn deal to buy Furiex
Furiex also has a stable of marketed drugs for diabetes including Nesina (alogliptin) and fixed-dose combination therapies Oseni/Liovel (alogliptin/pioglitazone) and Kazan (alogliptin/metformin), which are sold by Takeda,
Latest news
-
FDA investigates pancreas risk of diabetes drugs
Newer DPP-4 inhibitors Tradjenta (linagliptin) from Boehringer Ingelheim and Takeda's alogliptin-based medicines (Nesina, Kazano and Oseni) are also affected.
-
Takeda gets FDA approval for alogliptin franchise in diabetes
Comprises Nesina, Oseni and Kazano. Takeda was celebrating at the end of last week after the FDA granted approval to three of its diabetes drug candidates. ... The US agency approved Takeda's DPP-4 inhibitor Nesina (alogliptin) - along with two
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
- FDA approves Gilead’s remdesivir for hospitalised COVID-19 patients
- Moderna completes enrolment of phase 3 COVID-19 vaccine trial
- Vaccine developers call on FDA to offer clarity on COVID-19 trials
- The other side of … blood cancer
- COVID-19 – a catalyst for technology adoption in clinical trials
PMHub
Frontera Group
Welcome to Frontera Group, where our agencies immerse you in the world of the patient...
Latest intelligence
- Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
- The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
- The other side of … blood cancer
- To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
- COVID-19 – a catalyst for technology adoption in clinical trials
- As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...
Quick links
Infographics
